Topic
What happens when you stop or switch?
Weight regain evidence, maintenance dosing research, and switching between drugs.
Coming Off Compounded Semaglutide: How the Transition WorksCompounded semaglutide is winding down. Moving to an FDA-approved product means a new prescription, a dose your prescriber has to map by hand, and no overlap between products. Here is how the transition works and what to bring to the appointment.Do You Have to Take Wegovy Forever?The label sets no stop date and obesity societies now strongly recommend continuing during maintenance - but two 2026 trials changed the question from whether to stop to whether you can use less.GLP-1 Maintenance Dose: What the Research SaysTwo 2026 randomized trials finally tested whether you can hold weight loss on less drug. Here is what they found, what the labels allow, and why 'microdosing' is still a marketing term rather than a protocol.Switching From Ozempic to Mounjaro: What to KnowOzempic and Mounjaro are diabetes drugs, so a switch involves blood sugar as well as weight. Here is what the labels say, what the switching studies found, and what changes about monitoring in the first three months.Switching From Wegovy to Zepbound: What to KnowThere is no FDA-approved dose conversion between semaglutide and tirzepatide. Here is what the labels actually say, what published switching data shows, and the questions worth asking before your first Zepbound dose.What Happens When You Stop Taking a GLP-1: The EvidenceRandomized trials, real-world databases and meta-analyses now give a fairly clear picture of what happens to weight, blood sugar, blood pressure and body composition after a GLP-1 stops - and where the numbers disagree.